# OnCo record paper-attard-lancet-oncol (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-attard-lancet-oncol/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-attard-lancet-oncol" ;
  schema:name "Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol"@en ;
  schema:description "Paper cited by one trial page, indexed on Europe PMC as PubMed record 37142371 and published in The Lancet Oncology; the citing page links this DOI, which is how the record was matched."@en ;
  schema:url <https://onco.cc/key-papers/paper-attard-lancet-oncol/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(23)00148-1>, <https://pubmed.ncbi.nlm.nih.gov/37142371/>, <https://europepmc.org/article/MED/37142371> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(23)00148-1> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Attard G, Murphy L, Clarke NW, et al." ;
  onco:trials <https://onco.cc/trials/stampede/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .